Clinical trials: MGUS
Waldenstrom Macroglobulinemia
Spanish Registry of Patients With IgM Monoclonal Gammopathies
Waldenström's macroglobulinemia (WM) is a B-cell lymphoproliferative disorder which is defined by bone marrow infiltration by small lymphocytes, lymphoplasmacytoid and plasma cells together with the presence of a detectable…
- Trial name
- PRAME (NCT05093153)
- Where
- 51 sites in Spain
- Volunteers
- 1,000 people
- Sponsor
- Fundación Española de Hematología y Hemoterapía
Chronic Myeloproliferative Disorders, Leukemia
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
RATIONALE: Antiemetic drugs, such as ondansetron, may help to reduce or prevent nausea and vomiting in patients with advanced cancer.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00006348
- Testing
- ondansetron
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Schnitzler Syndrome
A Study to Assess the Effectiveness and Safety of Canakinumab in Clinical Use in Patients With Schnitzler's Syndrome
The aim of this study is to assess the effectiveness and safety of Ilaris (canakinumab) in clinical use in patients with Schnitzler's syndrome.
- Trial name
- NCT07598422
- Where
- 5 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Schnitzler Syndrome
Ilaris (Canakinumab) in the Schnitzler Syndrome
Schnitzler syndrome: Schnitzler syndrome is a rare disabling autoinflammatory syndrome characterized by a chronic urticarial rash and monoclonal gammopathy, accompanied by intermittent fever, arthralgia or arthritis or bone pain.
- Trial name
- NCT01245127
- Testing
- Ilaris
- Where
- Belgium
- Volunteers
- 1 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Dysglobulinemia
Familial Dysglobulinemia
Multiple Myeloma (MM) is a malignant proliferation of monoclonal plasma cells. Myeloma accounts for almost 14% of all hematologic cancers and is essentially incurable.
- Trial name
- PreFamDys (NCT02853214)
- Testing
- Genetic analysis of peripheral blood samples
- Where
- 47 sites in France
- Volunteers
- 1,868 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)
Escalating doses of Omega 3 Fatty Acids are being used in patients who have early stage Chronic Lymphocytic Leukemia (ES-CLL), Monoclonal Gammopathy of Undetermined Significance (MGUS), or Smoldering Multiple Myeloma (SMM), whose…
- Conditions
- Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, Chronic Lymphocytic Leukemia
- Trial name
- NCT00899353
- Testing
- Omega 3 Fatty Acid
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Marshall University
Multiple Myeloma, Smoldering, Multiple Myeloma
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
The researchers are going this to look at how butyrate levels change in participants' stool after they are on a plant-based diet or dietary supplements (omega-3, curcumin or probiotics) for 2 weeks.
- Conditions
- Multiple Myeloma, Smoldering, Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
- Trial name
- NCT06055894
- Testing
- Omega-3, Curcumin, Probiotic
- Where
- 7 sites in United States
- Volunteers
- 200 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Anti MAG Neuropathy
This Study Aims to Investigate the Efficacy of Photobiomodulation in the Treatment of Anti-MAG-induced Peripheral Neuropathy (LASER-MAG)
Patients treated in the hematology department of the Quimper/Cornouaille Hospital Center for IgM monoclonal gammopathy with anti-MAG and symptomatic peripheral neuropathy often reach a therapeutic impasse.
- Trial name
- LASER-MAG (NCT07661667)
- Testing
- photobiomodulation
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Centre Hospitalier de Cornouaille
Anemia, Leukemia
Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer
RATIONALE: Epoetin alfa may cause the body to make more red blood cells. It is used to treat anemia caused by cancer and chemotherapy.
- Conditions
- Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00255749
- Testing
- epoetin alfa
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003331
- Testing
- fluorouracil, leucovorin calcium, topotecan hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- NYU Langone Health
Monoclonal Gammopathy of Undetermined Significance, Smoldering Myeloma
Exploring the Effects of Korean-Style Mediterranean Diet (KORMED) and Physical Activity Measurement in Patients With MGUS/SMM: A Pilot Study
This single-arm pilot study aims to evaluate the feasibility and potential health effects of a Korean-style Mediterranean diet (KORMED) and continuous physical activity measurement in patients with monoclonal gammopathy of…
- Trial name
- KORMED-PA Stud (NCT07305662)
- Testing
- KORMED Diet and Physical Activity Monitoring
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Seoul National University Bundang Hospital
Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma
Establishment of Genomic, Transcriptomic and Functional Characteristics of Tumor Cells in Hyperinflammatory Hemopathies
Patients with monoclonal gammopathies either benign or malignant may develop inflammatory symptoms such as Schnitzler syndrome. We proposed to name those cases as monoclonal gammopathy of inflammatory significance, or MGIS.
- Conditions
- Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Waldenstrom Macroglobulinemia
- Trial name
- GEN-HEMO-INF (NCT04702932)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Monoclonal Gammopathy, Smoldering Myeloma
Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma
The purpose of this study is to study the safety and preliminary efficacy of a dendritic cell DKK1 vaccine against myeloma. Dendritic cells are immune cells that are collected from the blood of the patient at Case Western Reserve…
- Conditions
- Monoclonal Gammopathy, Smoldering Myeloma, Myeloma
- Trial name
- NCT03591614
- Testing
- DKK1
- Where
- 2 sites in United States
- Sponsor
- Case Comprehensive Cancer Center
Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma
B-Cell Hematologic Malignancy Vaccination Registry
The goal of this study is to develop a vaccination registry system for Aurora Health Care patients newly diagnosed with MM and other B-Cell Hematologic Malignancies in order to prospectively characterize vaccination history and…
- Conditions
- Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Waldenstrom Macroglobulinemia, Lymphocytosis
- Trial name
- HMvax-Regist (NCT02298816)
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Chronic Myeloproliferative Disorders, Leukemia
Treatment for Chronic Pain in Patients With Advanced Cancer
RATIONALE: Different drug formulations and combinations of drugs may help patients with chronic pain live more comfortably. It is not yet known which regimen is most effective for chronic pain.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003687
- Testing
- dextromethorphan hydrobromide, morphine sulfate
- Where
- 4 sites in Canada
- Volunteers
- 87 people
- Sponsor
- NCIC Clinical Trials Group
Chronic Myeloproliferative Disorders, Fatigue
American Ginseng in Treating Patients With Fatigue Caused by Cancer
RATIONALE: American ginseng may reduce fatigue in patients with cancer. It is not yet known whether American ginseng is more effective than a placebo in treating cancer-related fatigue.
- Conditions
- Chronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma
- Trial name
- NCT00719563
- Testing
- American ginseng
- Where
- 326 sites in United States
- Volunteers
- 364 people
- Sponsor
- Alliance for Clinical Trials in Oncology
IgA Monoclonal Gammopathy of Undetermined Significance, Non-IgM Monoclonal Gammopathy of Undetermined Significance
Rifaximin Versus No Intervention for the Treatment of IgG/IgA (Non-IgM) Monoclonal Gammopathy of Undetermined Significance
This phase II trial compares the effect of rifaximin to no intervention for the treatment of IgG/IgA monoclonal gammopathy of undetermined significance (MGUS).
- Trial name
- NCT07209371
- Testing
- Rifaximin, Biospecimen Collection
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
AL Amyloidosis, Smoldering Multiple Myeloma
Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
The investigators plan to establish a dedicated network of Italian Hematologic Departments interconnected with the Amyloidosis Research and Treatment Center in Pavia to: 1.
- Conditions
- AL Amyloidosis, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
- Trial name
- ProDigALIty (NCT06383143)
- Testing
- no intervention
- Where
- 4 sites in Italy
- Volunteers
- 760 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Multiple Myeloma, Multiple Myeloma Progression
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
The purpose of this study is to identify multiple myeloma in the precancerous MGUS stage in order to reduce the risk of delayed diagnosis of multiple myeloma, decrease morbidity related to multiple myeloma at progression, and…
- Conditions
- Multiple Myeloma, Multiple Myeloma Progression, Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM)
- Trial name
- NCT06644625
- Testing
- Blood draw for the laboratory assessment
- Where
- United States
- Volunteers
- 1,665 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Chronic Myeloproliferative Disorders, Leukemia
Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer
Phase I trial to study the effectiveness of combining interleukin-12 and interferon alfa in treating patients who have residual, recurrent, or metastatic malignant melanoma or other advanced cancer that has not responded to…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003451
- Testing
- recombinant interferon alfa, recombinant interleukin-12
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)